Holen Sie sich die Stockscreener-App
14.85
0.27%
-0.04
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus - MSN
Immunovant price target lowered to $35 from $51 at H.C. Wainwright - TipRanks
Immunovant’s Promising Future: Buy Rating Backed by Strategic Advancements and Strong Cash Position - TipRanks
Immunovant Inc reports results for the quarter ended March 31Earnings Summary - TradingView
H.C. Wainwright Adjusts Price Target for Immunovant (IMVT) Amid Future Prospects | IMVT Stock News - GuruFocus
Immunovant Insiders Sell US$5.9m Of Stock, Possibly Signalling Caution - simplywall.st
Immunovant (NASDAQ:IMVT) Shares Gap Up After Better-Than-Expected Earnings - Defense World
Immunovant, Inc. Reports Strategic Progress and Financial Results - TipRanks
IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm - PR Newswire
Immunovant, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 - marketscreener.com
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence - MSN
Immunovant, Inc. SEC 10-K Report - TradingView
Immunovant (IMVT) Secures Strong Financial Position with $714 Million in Cash | IMVT Stock News - GuruFocus
Earnings Flash (IMVT) IMMUNOVANT INC. Reports Q4 Loss $0.64 Per Share, vs. FactSet Est of $-0.71 - marketscreener.com
Immunovant's Clinical Trials Show 74% Success in Myasthenia Gravis, Advancing 6 Disease Programs - Stock Titan
Immunovant (IMVT) to Release Earnings on Wednesday - Defense World
Bank of America Corp DE Buys 114,511 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
(IMVT) Trading Advice - news.stocktradersdaily.com
IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm - Business Wire
Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Target Price at $38.33 - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by Northern Trust Corp - Defense World
Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings? - Insider Monkey
The Manufacturers Life Insurance Company Has $889,000 Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Transcript : Immunovant, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04 - marketscreener.com
Smart Money Ratings For 20 Most Undervalued Stocks - Insider Monkey
Immunovant Inc (NASDAQ: IMVT) Is The Among Hot Stock Right Now - Stocksregister
Dimensional Fund Advisors LP Sells 58,463 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back? - Insider Monkey
Raymond James Financial Inc. Buys Shares of 20,382 Immunovant, Inc. (NASDAQ:IMVT) - Defense World
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Investor’s Delight: Immunovant Inc (IMVT) Closes Weak at 15.22, Down -3.67 - DWinneX
Ins & Outs: Biopharma players shuffle c-suite ranks - BioProcess International
(IMVT) Investment Analysis - news.stocktradersdaily.com
Immunovant, Inc. (NASDAQ:IMVT) Shares Acquired by Wells Fargo & Company MN - Defense World
A company insider recently sold 1,925 shares of Immunovant Inc [IMVT]. Should You Sale? - knoxdaily.com
IMVT’s Stock Market Adventure: -34.80% YTD Growth Amidst Volatility - investchronicle.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharma - Barchart.com
Perhaps timely catching Immunovant Inc (IMVT) would be a good idea - Sete News
Immunovant registers shares for selling stockholders - MSN
Potential Price Increase for Immunovant Inc (IMVT) After Recent Insider Activity - knoxdaily.com
Market Watch Highlights: Immunovant Inc (IMVT) Ends on an Downturn Note at 14.72 - DWinneX
Stock Market Recap: Immunovant Inc (IMVT) Concludes at 14.58, a -7.60 Surge/Decline - DWinneX
Renaissance Technologies LLC Sells 108,100 Shares of Immunovant, Inc. (NASDAQ:IMVT) - The AM Reporter
Immunovant, Inc. (NASDAQ:IMVT) Receives $38.33 Average PT from Analysts - Defense World
Immunovant’s (IMVT) “Neutral” Rating Reiterated at UBS Group - Defense World
Immunovant Inc [IMVT] Records 50-Day SMA of $18.03 - knoxdaily.com
All change at Immunovant as Pete Salzmann retires - The Pharma Letter
UBS Downgrades Immunovant to Neutral, Price Target is $17 - marketscreener.com
Upward Trajectory: Immunovant Inc (IMVT) Posts a Slidee, Closing at 14.46 - DWinneX
Trial of Sjögren's treatment IMVT-1402 slated to launch in summer - Sjogren's Syndrome News
Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus - insights.citeline.com
Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated - NewsBreak: Local News & Alerts
Immunovant Names New CEO, CFO - marketscreener.com
Roivant Sciences Announces Leadership Changes at Immunovant - TipRanks
Immunovant Announces New CEO Amid Strategic Shift - TipRanks
Immunovant (IMVT) Appoints New CEO Amid Strategic Changes - GuruFocus
Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications - TradingView
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 - The Manila Times
Immunovant (IMVT) Announces Leadership Changes - StreetInsider
Immunovant's Major Growth Push: Drug Pipeline Hits 6 Indications as Roivant Executive Takes CEO Role - Stock Titan
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):